AKTX - Conference and earnings call announcements

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and Chin

Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026  Register for the event here TAMPA, Fla. and LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026. Management will discuss the Company's differentiated ADC pipeline, including progress across i

TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will present at the 2026 Biocom Global Partnering & Investor Conference, being held February 24–26, 2026, at The Lodge at Torrey Pines in San Diego, CA. Presentation details are as follows: Date/Time: Wednesday, February 25, 2026, at 11:00 AM PSTLocation: Track B In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qu

– Live video webcast on Tuesday, February 10th at 1:00 PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the presentation, Abizer Gaslightwala, Director, President and CEO of Akari Therapeutics, will provide a corporate overview highlighting the Company's next-generation antibody drug conjugate platform and proprietary PH1 spliceosome-modulatin

In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the 2026 Biotech Showcase being held from January 12-14, 2026 in San Francisco, CA. Presentation details are as follows: Date/Time: Tuesday, January 13, 2026 at 9:30 AM PSTL

BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York, NY.  In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference web

Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, September 4, 2025 at 4:00 PM ET. As part of the event, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will provide a corporate overview and discuss its innovative payload platform fueling a pipeline of next-generation ADCs designed with novel immun

BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Gaslightwala, President and Chief Executive Officer of AkariRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed

BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET. Conference Details: Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29th at 2:20 PM ET Presenter: Abizer Gaslightwala, Director, President and CEORegistration Link: HERE About Webull Financial Webull Financial is a

NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences. Date:  Monday, January 8, 2024Time:  9:30AM PSTPlace:  Yosemite A (Ballroom Level) About Akari TherapeuticsAkari Therapeutics, plc (NASDAQ:AKTX) is a biotechnology co

BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET. Register for the presentation at https://goto.webcasts.com/starthere.jsp?ei=1603287&tp_key=5580ab2cb9&sti=aktx. Questions may be submitted in advance at Q

Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON and LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will host a virtual key opinion leader event on October 19, 2023 at 11:30 am ET to discuss the patient care landscape for hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and the significant needs that exist for earlier diagnosis and approved treatment options. The potential of Akari's investigational nomacopan, a novel bispecific inhibitor of both comple

NEW YORK and LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in Alliance Global Partners' Virtual Healthcare Conference being held May 23-24, 2023. During the event, the Akari management team will attend 1:1 investor meetings. About Akari Therapeutics Akari Therapeutics, plc (NASDAQ:AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and l

Event on May 22nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of Medicine NEW YORK and LONDON, April 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will host a virtual key opinion leader event on May 22, 2023 at 2 pm ET to discuss the treatment landscape in geographic atrophy (GA) and the potential for long-acting PAS-nomacopan to address significant unmet needs. Akari's lead asset is investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (L

NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari's two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical prog

NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Ophthalmology Day at BTIG on November 29, 2022. President and CEO Rachelle Jacques will participate in a fireside chat scheduled for 9:30 am ET. Akari will be discussing progress in the development of long-acting PAS-nomacopan in geographic atrophy (GA), including positive results from recent pre-clinical studies that support possible advancement toward IND/IMPD for clinical trials in GA and the potential to address significant unmet p

NEW YORK and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Jefferies London Healthcare Conference scheduled to take place November 15-17, 2022. President and CEO Rachelle Jacques and the Akari management team will attend 1:1 meetings with investors who are registered for the conference. About Akari Therapeutics Akari Therapeutics, plc (NASDAQ:AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan,

NEW YORK and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Sidoti November Virtual Micro-Cap Conference on November 9, 2022. President and CEO Rachelle Jacques will present a company overview at 1:45 pm Eastern time and the management team will attend scheduled 1:1 investor meetings. Investors registered for the conference may schedule 1:1 meetings with Akari through the Sidoti conference website. A recording will be available at akaritx.com following the company presentation. About Akari The

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Cantor Oncology & HemOnc Conference on September 28, 2022. President and CEO Rachelle Jacques will take part in a conference panel, Addressing Challenges in Cell Therapy and Transplant, at 9:00 a.m. Eastern time and will attend 1:1 investor meetings. About Akari Therapeutics Akari Therapeutics, plc (NASDAQ:AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's

NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer of Akari Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:30 p.m. ET, at the New York Marriott Marquis. The Company's live presentation will be made available through the BIO CEO & Investor Conference website and available on-demand to registered participants during t

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present a Company overview at the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. The pre-recorded presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. ET by visiting ‘Events' in the Investor Relations section of the Company's website at www.akaritx.com. A webcast replay wil

NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET. Investors interested in arranging a virtual meeting with the Company's management during the conference should contact the Cantor conference coordinator. A webcast of the Company's presentation will be available by visiting ‘E

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. Investors interested in arranging a virtual meeting with the Company's management during the conference should contact the H.C. Wainwright conference coordinator. A webcast of the Company's presentation will be avail

NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will participate in the following two upcoming virtual investor conferences.   Conference:H.C. Wainwright BioConnect ConferenceDate & Time:The Company’s presentation will be available on demand starting January 11, 2021 through the Company’s website.  Conference:ICR Conference 2021Date & Time:Thursday, January 14, 2021 at 10:00 a.m. ET.